Under the agreement, the two companies will work to develop affinity-based products for use in the production processes for protein-based pharmaceuticals. The development of these products will be based on Affibodies™, a novel class of small, robust affinity proteins designed to bind desired protein targets. Financial details of the agreement were not disclosed.
“The use of Affibodies™ opens up new possibilities for large-scale protein purification for production of protein based pharmaceuticals. We are very pleased that we can continue to build value through our successful collaboration with Affibody”, said Peter Ehrenheim, Vice President of Protein Separations at Amersham Biosciences.
Affibody and Amersham Biosciences have a successful ongoing collaboration, which was initiated two years ago. For Amersham Biosciences, the newly initiated collaboration entails an expansion of the Company’s research portfolio regarding products for purification, i.e. affinity chromatography.
Torben Jørgensen | alphagalileo
The interactome of infected neural cells reveals new therapeutic targets for Zika
23.01.2017 | D'Or Institute for Research and Education
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
23.01.2017 | Life Sciences
23.01.2017 | Materials Sciences
20.01.2017 | Awards Funding